• 1
    Hughes DA, Bagust A, Haycox A, Walley T. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ 2001;10:60115.
  • 2
    Lewis A. Noncompliance: a $100 billion problem. Remington Report 1997;5:145.
  • 3
    World Health Organization. Adherence to long-term therapies: evidence for action. 2003. Available from:[Accessed December 12, 2007].
  • 4
    Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:48797.
  • 5
    Saaddine JB, Engelgau MM, Beckles GL, et al. A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med 2002;136:56574.
  • 6
    Kerr EA, Gerzoff RB, Krein SL, et al. Diabetes care quality in the Veterans Affairs Health Care System and commercial managed care: the TRIAD study. Ann Intern Med 2004;141:27281.
  • 7
    American Diabetes Association. Standards of medical care in diabetes—2007. Diabetes Care 2007;30:S441.
  • 8
    Abegunde DO, Mathers CD, Adam T, et al. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 2007;370:192938.
  • 9
    Clarke P, Gray A, Legood R, et al. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003;20:44250.
  • 10
    Pohar SL, Majumdar SR, Johnson JA. Health care costs and mortality for Canadian urban and rural patients with diabetes: population-based trends from 1993–2001. Clin Ther 2007;29:131624.
  • 11
    Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:40512.
  • 12
    UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:85465.
  • 13
    Salas M, Ward A, Caro J. Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus. Clin Ther 2002;24:1690705.
  • 14
    Balu S. Incremental treatment expenditure of diabetes in the United States. Manag Care Interface 2007;20:207.
  • 15
    Valentine WJ, Erny-Albrecht KM, Ray JA, et al. Therapy conversion to insulin among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States. Adv Ther 2007;24:27390.
  • 16
    Pawaskar MD, Camacho FT, Anderson RT, et al. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther 2007;29:1294305.
  • 17
    Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006;28:171225.
  • 18
    Kalsekar I, Iyer S, Mody R, et al. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population. J Manag Care Pharm 2006;12:1219.
  • 19
    Lee WC, Balu S, Cobden D, et al. Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review. Manag Care Interface 2006;19:3141.
  • 20
    Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:121824.
  • 21
    Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006;166:183641.
  • 22
    Gerstein HC. Glycosylated hemoglobin: finally ready for prime time as a cardiovascular risk factor. Ann Int Med 2004;141: 4756.
  • 23
    Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11: 447.
  • 24
    American Diabetes Association. Standards of medical care in diabetes—2009. Diabetes Care 2009;32(Suppl. 1):S1361. Available from:[Accessed January 5, 2009.
  • 25
    Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:42131.
  • 26
    Rozenfeld Y, Hunt JS, Plauschinat C, Wong KS. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care 2008;14:715.
  • 27
    Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313:27583.
  • 28
    Balkrishnan R, Rajagopalan R, Camacho FT, et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther 2003;25:295871.
  • 29
    Cobden D, Lee WC, Balu S, et al. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy 2007;27:94862.
  • 30
    Balkrishnan R, Rajagopalan R, Shenolikar RA, et al. Healthcare costs and prescription adherence with introduction of thiazolidinedione therapy in Medicaid type 2 diabetic patients: a retrospective data analysis. Curr Med Res Opin 2004;20:163340.
  • 31
    Hepke KL, Martus MT, Share DA. Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care 2004;10:14451.
  • 32
    Shenolikar RA, Balkrishnan R, Camacho FT, et al. Comparison of medication adherence and associated health care costs after introduction of pioglitazone treatment in African Americans versus all other races in patients with type 2 diabetes mellitus: a retrospective data analysis. Clin Ther 2006;28:1199207.
  • 33
    Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:52130.
  • 34
    Wagner EH, Sandhu N, Newton KM, et al. Effect of improved glycemic control on health care costs and utilization. JAMA 2001;285:1829.
  • 35
    White TJ, Vanderplas A, Chang E, et al. The costs of non-adherence to oral antihyperglycemic medication in individuals with diabetes mellitus and concomitant diabetes mellitus and cardiovascular disease in a managed care environment. Dis Manage Health Outcomes 2004;12:1818.
  • 36
    Shetty S, Secnik K, Oglesby AK. Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes. J Manag Care Pharm 2005;11:55964.
  • 37
    Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:312.
  • 38
    Hughes D, Cowell W, Koncz T, Cramer J, International Society for Pharmacoeconomics & Outcomes Research Economics of Medication Compliance Working Group. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value Health 2007;10:498509.
  • 39
    Johnson JA, Pohar SL, Majumdar SR. Health care use and costs in the decade after identification of type 1 and type 2 diabetes: a population-based study. Diabetes Care 2006;29:24038.
  • 40
    Pohar SL, Majumdar SR, Jacobs P, Johnson JA. Healthcare Utilization and Direct Healthcare Costs of Diabetes in Urban and Rural Saskatchewan, 1991–2001. Edmonton: Alliance for Canadian Health Outcomes Research in Diabetes, 2006 (Institute of Health Economics Working Paper WP 06-1).
  • 41
    Liu L, Hader J, Brossart B, et al. Impact of rural hospital closures in Saskatchewan, Canada. Soc Sci Med 2001;52:1793804.
  • 42
    Phillips PJ. Gestational diabetes. Aust Fam Physician 2006;35:7013.
  • 43
    Newton KM, Wagner EH, Ramsey SD, et al. The use of automated data to identify complications and comorbidities of diabetes: a validation study. J Clin Epidemiol 1999;52:199207.
  • 44
    Wilchesky M, Tamblyn RM, Huang A. Validation of diagnostic codes within medical services claims. J Clin Epidemiol 2004;57:13141.
  • 45
    Grymonpre R, Cheang M, Fraser M, et al. Validity of a prescription claims database to estimate medication adherence in older persons. Med Care 2006;44:4717.
  • 46
    Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci 2007;48:50527.
  • 47
    Ragnarson Tennvall G, Apelqvist J, Eneroth M. The inpatient care of patients with diabetes mellitus and foot ulcers. A validation study of the correspondence between medical records and the Swedish Inpatient Registry with the consequences for cost estimations. J Intern Med 2000;248:397405.
  • 48
    Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006;40:128088.
  • 49
    Zeller A, Schroeder K, Peters T. Cigarette smoking and adherence to antihypertensive medication in patients from primary care. Eur J Gen Pract 2007;13:1612.
  • 50
    Vik SA, Hogan DB, Patten SB, et al. Medication nonadherence and subsequent risk of hospitalisation and mortality among older adults. Drugs Aging 2006;23:34556.
  • 51
    Cook RL, Sereika SM, Hunt SC, et al. Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med 2001;16:836.
  • 52
    Palepu A, Horton NJ, Tibbetts N, et al. Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: the impact of substance abuse treatment. Addiction 2004;99:3618.
  • 53
    Tucker JS, Burnam MA, Sherbourne CD, et al. Substance use and mental health correlates of nonadherence to antiretroviral medication in a sample of patients with Human Immunodeficiency Virus Infection. Am J Med 2003;114:57380.
  • 54
    Jonsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with type 2 diabetes in Sweden. Value Health 2006;9:1938.
  • 55
    Finkler SA. The distinction between cost and charges. Ann Intern Med 1982;96:1029.
  • 56
    Rutten-van Mölken MP, Van Doorslaer EK, Van Vliet RC. Statistical analysis of cost outcomes in a randomized controlled clinical trial. Health Econ 1994;3:33345.
  • 57
    Dodd S, Bassi A, Bodger K, Williamson P. A comparison of multivariable regression models to analyze cost data. J Eval Clin Pract 2006;12:7686.